WO2001090156A3 - Card domain containing polypeptides, encoding nucleic acids, and methods of use - Google Patents

Card domain containing polypeptides, encoding nucleic acids, and methods of use Download PDF

Info

Publication number
WO2001090156A3
WO2001090156A3 PCT/US2001/017158 US0117158W WO0190156A3 WO 2001090156 A3 WO2001090156 A3 WO 2001090156A3 US 0117158 W US0117158 W US 0117158W WO 0190156 A3 WO0190156 A3 WO 0190156A3
Authority
WO
WIPO (PCT)
Prior art keywords
encoding nucleic
containing polypeptides
methods
nucleic acids
domain containing
Prior art date
Application number
PCT/US2001/017158
Other languages
French (fr)
Other versions
WO2001090156A2 (en
Inventor
John C Reed
Frederick F Pio
Adam Godzik
Christian Stehlik
Jason S Damiano
Sug Hyung Lee
Vasco A M Oliveira
Hideki Hayashi
Krzysztof Pawlowski
Original Assignee
Burnham Inst
John C Reed
Frederick F Pio
Adam Godzik
Christian Stehlik
Jason S Damiano
Sug Hyung Lee
Vasco A M Oliveira
Hideki Hayashi
Krzysztof Pawlowski
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/864,921 external-priority patent/US7196182B2/en
Application filed by Burnham Inst, John C Reed, Frederick F Pio, Adam Godzik, Christian Stehlik, Jason S Damiano, Sug Hyung Lee, Vasco A M Oliveira, Hideki Hayashi, Krzysztof Pawlowski filed Critical Burnham Inst
Priority to JP2001586967A priority Critical patent/JP2003533997A/en
Priority to CA002410096A priority patent/CA2410096A1/en
Priority to EP01939529A priority patent/EP1297129A2/en
Priority to AU2001265036A priority patent/AU2001265036A1/en
Publication of WO2001090156A2 publication Critical patent/WO2001090156A2/en
Publication of WO2001090156A3 publication Critical patent/WO2001090156A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • Tropical Medicine & Parasitology (AREA)

Abstract

The invention provides caspase recruitment domain (CARD) -containing polypeptides, CARD, NB-ARC, ANGIO-R, LRR and SAM domains therefrom, as well as encoding nucleic acid molecules and specific antibodies. The invention also provides related screening, diagnostic and therapeutic methods.
PCT/US2001/017158 2000-05-24 2001-05-24 Card domain containing polypeptides, encoding nucleic acids, and methods of use WO2001090156A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
JP2001586967A JP2003533997A (en) 2000-05-24 2001-05-24 CARD domain containing polypeptides, encoding nucleic acids and methods of use
CA002410096A CA2410096A1 (en) 2000-05-24 2001-05-24 Card domain containing polypeptides, encoding nucleic acids, and methods of use
EP01939529A EP1297129A2 (en) 2000-05-24 2001-05-24 Card domain containing polypeptides, encoding nucleic acids, and methods of use
AU2001265036A AU2001265036A1 (en) 2000-05-24 2001-05-24 Card domain containing polypeptides, encoding nucleic acids, and methods of use

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US57924000A 2000-05-24 2000-05-24
US09/579,240 2000-05-24
US68634700A 2000-10-10 2000-10-10
US09/686,347 2000-10-10
US27598001P 2001-03-14 2001-03-14
US60/275,980 2001-03-14
US09/864,921 2001-05-23
US09/864,921 US7196182B2 (en) 2000-05-24 2001-05-23 Card domain containing polypeptides, encoding nucleic acids, and methods of use

Publications (2)

Publication Number Publication Date
WO2001090156A2 WO2001090156A2 (en) 2001-11-29
WO2001090156A3 true WO2001090156A3 (en) 2003-01-16

Family

ID=27501148

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/017158 WO2001090156A2 (en) 2000-05-24 2001-05-24 Card domain containing polypeptides, encoding nucleic acids, and methods of use

Country Status (5)

Country Link
EP (1) EP1297129A2 (en)
JP (1) JP2003533997A (en)
AU (1) AU2001265036A1 (en)
CA (1) CA2410096A1 (en)
WO (1) WO2001090156A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1238201A (en) * 1999-10-27 2001-05-08 Millennium Pharmaceuticals, Inc. Novel molecules and the card-related protein family and uses thereof
US6858391B2 (en) 2000-10-30 2005-02-22 Regents Of The University Of Michigan Nod2 nucleic acids and proteins
ES2400552T3 (en) 2000-10-30 2013-04-10 The Regents Of The University Of Michigan NOD2 nucleic acids and proteins
US20030166192A1 (en) * 2001-01-16 2003-09-04 Alnemri Emad S. Inhibition of interleukin-1-beta secretion by card proteins
AU2003235685A1 (en) * 2002-01-09 2003-07-30 Ruslan M. Medzhitov Rip2: a method of signaling in the innate and adaptive immune systems

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012016A1 (en) * 1994-10-18 1996-04-25 The University Of Ottawa Neuronal apoptosis inhibitor protein, gene sequence and mutations causative of spinal muscular atrophy
WO1999040102A1 (en) * 1998-02-06 1999-08-12 Millennium Pharmaceuticals, Inc. Novel molecules of the card-related protein family and uses thereof
WO2001000826A2 (en) * 1999-06-28 2001-01-04 Millennium Pharmaceuticals, Inc. Novel molecules of the card-related protein family and uses thereof
WO2001018042A2 (en) * 1999-09-10 2001-03-15 Incyte Genomics, Inc. Apoptosis proteins
WO2001030971A2 (en) * 1999-10-27 2001-05-03 Millennium Pharmaceuticals, Inc. Novel molecules and the card-related protein family and uses thereof
WO2001066690A2 (en) * 2000-03-06 2001-09-13 Smithkline Beecham Corporation Novel compounds
WO2001072822A2 (en) * 2000-03-27 2001-10-04 Fondation Jean Dausset-Ceph Genes involved in intestinal inflammatory diseases and use thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996012016A1 (en) * 1994-10-18 1996-04-25 The University Of Ottawa Neuronal apoptosis inhibitor protein, gene sequence and mutations causative of spinal muscular atrophy
WO1999040102A1 (en) * 1998-02-06 1999-08-12 Millennium Pharmaceuticals, Inc. Novel molecules of the card-related protein family and uses thereof
WO2001000826A2 (en) * 1999-06-28 2001-01-04 Millennium Pharmaceuticals, Inc. Novel molecules of the card-related protein family and uses thereof
WO2001018042A2 (en) * 1999-09-10 2001-03-15 Incyte Genomics, Inc. Apoptosis proteins
WO2001030971A2 (en) * 1999-10-27 2001-05-03 Millennium Pharmaceuticals, Inc. Novel molecules and the card-related protein family and uses thereof
WO2001066690A2 (en) * 2000-03-06 2001-09-13 Smithkline Beecham Corporation Novel compounds
WO2001072822A2 (en) * 2000-03-27 2001-10-04 Fondation Jean Dausset-Ceph Genes involved in intestinal inflammatory diseases and use thereof

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
BERTIN JOHN ET AL: "Human CARD4 protein is a novel CED-4/Apaf-1 cell death family member that activates NF-kappaB", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 274, no. 19, 7 May 1999 (1999-05-07), pages 12955 - 12958, XP002160787, ISSN: 0021-9258 *
DAMIANO J S ET AL: "CLAN, a novel human CED-4-like gene.", GENOMICS. UNITED STATES JUL 2001, vol. 75, no. 1-3, July 2001 (2001-07-01), pages 77 - 83, XP002212424, ISSN: 0888-7543 *
DATABASE EMBL [online] 10 December 1999 (1999-12-10), BIRREN B. ET AL.: "Homo sapiens chromosome 4 clone RP11-94C22 map 4, LOW-PASS SEQUENCE SAMPLING", XP002200584, retrieved from EBI Database accession no. AC016492 *
DATABASE EMBL [online] 16 March 2000 (2000-03-16), "Homo sapiens chromosome 5 clone CTD-2235A13, WORKING DRAFT SEQUENCE, 16 ordered pieces.", XP002200583, retrieved from EBI Database accession no. AC025758 *
DATABASE EMBL [online] 20 March 2000 (2000-03-20), "Homo sapiens chromosome 5 clone CTD-2303L1, complete sequence.", XP002200585, retrieved from EBI Database accession no. AC026732 *
DATABASE EMBL [online] 7 June 1999 (1999-06-07), BRUCE D. ET AL.: "Homo sapiens chromosome 16 clone RP11-327f22 , complete sequence", XP002212609, retrieved from EBI Database accession no. AC007728 *
DATABASE EMBL [online] WATERSTON R.H.: "Homo sapiens chromosome 2 clone RP11-93O2, WORKING DRAFT SEQUENCE, 11 unordered pieces", XP002212426, retrieved from EBI Database accession no. AC010968 *
DATABASE EMBL [online] ZHAO S ET AL.: "RPCI-11-384F21.TJ RPCI-11 Homo sapiens genomic clone RPCI-11-384F21, genomic survey sequence", XP002212427, retrieved from EBI Database accession no. AQ534686 *
GEDDES B J ET AL: "Human CARD12 is a novel CED4/Apaf-1 family member that induces apoptosis.", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS. UNITED STATES 1 JUN 2001, vol. 284, no. 1, 1 June 2001 (2001-06-01), pages 77 - 82, XP002212423, ISSN: 0006-291X *
HOFMANN K ET AL: "The CARD domain: a new apoptotic signalling motif", TIBS TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER PUBLICATION, CAMBRIDGE, EN, vol. 22, no. 5, 1 May 1997 (1997-05-01), pages 155 - 156, XP004061753, ISSN: 0968-0004 *
KOBE B ET AL: "PROTEINS WITH LEUCINE-RICH REPEATS", CURRENT OPINION IN STRUCTURAL BIOLOGY, CURRENT BIOLOGY LTD., LONDON, GB, vol. 3, no. 5, 1995, pages 409 - 416, XP001074047, ISSN: 0959-440X *
KOONIN E V ET AL: "The NACHT family - a new group of predicted NTPases implicated in apoptosis and MHC transcription activation", TIBS TRENDS IN BIOCHEMICAL SCIENCES, ELSEVIER PUBLICATION, CAMBRIDGE, EN, vol. 25, no. 5, May 2000 (2000-05-01), pages 223 - 224, XP004198165, ISSN: 0968-0004 *
OGURA ET AL: "Nod2, a Nod1/Apaf-1 Family Member That Is Restricted to Monocytes and Activates NF-kappa B", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY OF BIOLOGICAL CHEMISTS, BALTIMORE, MD, US, vol. 276, no. 7, 16 February 2001 (2001-02-16), pages 4812 - 4818, XP002177307, ISSN: 0021-9258 *
POYET J L ET AL: "Identification of Ipaf, a human caspase-1-activating protein related to Apaf-1.", THE JOURNAL OF BIOLOGICAL CHEMISTRY. UNITED STATES 27 JUL 2001, vol. 276, no. 30, 27 July 2001 (2001-07-27), pages 28309 - 28313, XP002212425, ISSN: 0021-9258 *
RYCHLEWSKI L ET AL: "COMPARISON OF SEQUENCE PROFILES. STRATEGIES FOR STRUCTURAL PREDICTIONS USING SEQUENCE INFORMATION", PROTEIN SCIENCE, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, vol. 2, no. 9, February 2000 (2000-02-01), pages 232 - 241, XP008001634, ISSN: 0961-8368 *
STAPLETON DAVID ET AL: "The crystal structure of an Eph receptor SAM domain reveals a mechanism for modular dimerization", NATURE STRUCTURAL BIOLOGY, NEW YORK, NY, US, vol. 6, no. 1, January 1999 (1999-01-01), pages 44 - 49, XP002134936, ISSN: 1072-8368 *

Also Published As

Publication number Publication date
WO2001090156A2 (en) 2001-11-29
CA2410096A1 (en) 2001-11-29
JP2003533997A (en) 2003-11-18
EP1297129A2 (en) 2003-04-02
AU2001265036A1 (en) 2001-12-03

Similar Documents

Publication Publication Date Title
MXPA02011656A (en) Nrg 2 nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods.
MXPA02012743A (en) Il-17 molecules and uses thereof.
EP2305715A3 (en) Monoclonal antibody to osteoprotegerin binding protein
WO2001055308A8 (en) Nucleic acids, proteins, and antibodies
WO1997008314A3 (en) Telomere repeat binding factor and diagnostic and therapeutic use thereof
WO2002029086A3 (en) Nucleic acid sequences differentially expressed in cancer tissue
AU8881201A (en) Tnf receptor-like molecules and uses thereof
WO2001061007A3 (en) Fibroblast growth factor-23 molecules and uses thereof
WO2001068859A3 (en) Il-17 receptor like molecules and uses thereof
DE69029808D1 (en) MONOCLONAL ANTIBODIES
WO2001042474A3 (en) Interferon-like molecules and uses thereof
WO2001090156A3 (en) Card domain containing polypeptides, encoding nucleic acids, and methods of use
MXPA03000979A (en) C3b/C4b COMPLEMENT RECEPTOR-LIKE MOLECULES AND USES THEREOF.
IL154298A0 (en) Papap proteins, their preparation and use
WO2003027251A3 (en) Novel molecules of the pyrin domain protein family and uses thereof
WO2001016317A3 (en) Polycyclic aromatic hydrocarbon induced molecules
WO2001059120A3 (en) Il-17 like molecules and uses thereof
WO2001066747A3 (en) Proteins named fctrx and nucleic acids encoding same
PL374550A1 (en) Il-17 like molecules and uses thereof
WO2001074903A3 (en) Cd20/ige-receptor like molecules and uses thereof
WO2001074851A3 (en) Novel proteins and nucleic acids encoding same
WO2000023466A3 (en) Human rna binding proteins
WO2002050276A3 (en) Proteins and nucleic acids encoding same
MXPA03000980A (en) C3b/c4b complement receptor-like molecules and uses thereof.
MXPA03010739A (en) Tumor endothelial marker 7 alpha molecules and uses thereof.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US US US US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2001265036

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2410096

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2001939529

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2001939529

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2001939529

Country of ref document: EP